Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between monoaminergic and melatonergic properties.
نویسنده
چکیده
ISSUE A striking and unexpected pharmacologic synergy has been shown between antagonist actions at serotonergic 5HT2C receptors, and agonist actions at melatonergic receptors by agomelatine, a drug that has both of these properties.
منابع مشابه
Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
There are many potentials for the development of more effective, better tolerated, and more rapidly acting antidepressants. As there is large prevalence of circadian dysfunction in various affective disorders, including depression, one of the approaches is the development of antidepressant drugs with melatonergic agonist properties. Agomelatine, with its melatonergic agonistic (at both MT(1) an...
متن کاملBeneficial behavioural and neurogenic effects of agomelatine in a model of depression/anxiety.
Agomelatine (S20098) is a novel antidepressant drug with melatonergic agonist and 5-HT2C receptor antagonist properties, displaying antidepressant/anxiolytic-like properties in animal models and in humans. In a depression/anxiety-like mouse model in which the response of the HPA axis is blunted, we investigated whether agomelatine could reverse behavioural deficits related to depression/anxiety...
متن کاملElectroretinographic modifications induced by agomelatine: a novel avenue to the understanding of the claimed antidepressant effect of the drug?
BACKGROUND Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the central nervous system dopaminergi...
متن کاملNovel mechanism of antidepressant action: norepinephrine and dopamine disinhibition (NDDI) plus melatonergic agonism.
All known antidepressants enhance monoamine neurotransmission, and most do so by blocking one or more of the reuptake transporters for serotonin, norepinephrine and/or dopamine (Stahl, 2000). Now comes agomelatine, a new agent that enhances norepinephrine and dopamine neurotransmission by a unique mechanism, namely 5-HT2C antagonism (Millan et al., 2003; Millan, 2005). Agomelatine is also a dir...
متن کاملAddressing circadian rhythm disturbances in depressed patients.
Desynchronisation of normal circadian rhythms, including the sleep-wake rhythm, is common in major depressive disorder (MDD). The association between sleep disturbances and depression has long been recognised. Disturbed sleep is a diagnostic criterion for MDD, and insomnia commonly precedes the onset of symptomatic mood disorders. Disruptions of the sleep-wake cycle (sleep architecture and timi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- CNS spectrums
دوره 19 3 شماره
صفحات -
تاریخ انتشار 2014